Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2014

Open Access 01-12-2014 | Protocol

Comparative safety of anti-epileptic drugs among infants and children exposed in utero or during breastfeeding: protocol for a systematic review and network meta-analysis

Authors: Andrea C Tricco, Elise Cogo, Veroniki A Angeliki, Charlene Soobiah, Brian Hutton, Brenda R Hemmelgarn, David Moher, Yaron Finkelstein, Sharon E Straus

Published in: Systematic Reviews | Issue 1/2014

Login to get access

Abstract

Background

Epilepsy affects about 1% of the general population. Anti-epileptic drugs (AEDs) prevent or terminate seizures in individuals with epilepsy. Pregnant women with epilepsy may continue taking AEDs. Many of these agents cross the placenta and increase the risk of major congenital malformations, early cognitive and developmental delays, and infant mortality. We aim to evaluate the comparative safety of AEDs approved for chronic use in Canada when administered to pregnant and breastfeeding women and the effects on their infants and children through a systematic review and network meta-analysis.

Methods

Studies examining the effects of AEDs administered to pregnant and breastfeeding women regardless of indication (e.g., epilepsy, migraine, pain, psychiatric disorders) on their infants and children will be included. We will include randomized clinical trials (RCTs), quasi-RCTs, non-RCTs, controlled before-after, interrupted time series, cohort, registry, and case-control studies. The main literature search will be executed in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. We will seek unpublished literature through searches of trial protocol registries and conference abstracts. The literature search results screening, data abstraction, and risk of bias appraisal will be performed by two individuals, independently. Conflicts will be resolved through discussion. The risk of bias of experimental and quasi-experimental studies will be appraised using the Cochrane Effective Practice and Organization of Care Risk-of-Bias tool, methodological quality of observational studies will be appraised using the Newcastle-Ottawa Scale, and quality of reporting of safety outcomes will be conducted using the McMaster Quality Assessment Scale of Harms (McHarm) tool. If feasible and appropriate, we will conduct random effects meta-analysis. Network meta-analysis will be considered for outcomes that fulfill network meta-analysis assumptions.
The primary outcome is major congenital malformations (overall and by specific types), while secondary outcomes include fetal loss/miscarriage, minor congenital malformations (overall and by specific types), cognitive development, psychomotor development, small for gestational age, preterm delivery, and neonatal seizures.

Discussion

Our systematic review will address safety concerns regarding the use of AEDs during pregnancy and breastfeeding. Our results will be useful to healthcare providers, policy-makers, and women of childbearing age who are taking anti-epileptic medications.

Systematic review registration

PROSPERO CRD42014008925.
Appendix
Available only for authorised users
Literature
1.
Hauser WA, Hesdorffer D: Epilepsy, Frequency, Causes and Consequences. 1990, New York: Demos Publications
2.
Wiebe S, Bellhouse DR, Fallahay C, Eliasziw M: Burden of epilepsy: the Ontario Health Survey. Can J Neurol Sci. 1999, 26 (4): 263-270.CrossRefPubMed
3.
Sperling MR: The consequences of uncontrolled epilepsy. CNS Spectr. 2004, 9 (2): 98-101. 106–109PubMed
4.
Jones MW: Consequences of epilepsy: why do we treat seizures?. Can J Neurol Sci. 1998, 25 (4): S24-S26.CrossRefPubMed
5.
Dickenson AH, Ghandehari J: Anti-convulsants and anti-depressants. Handb Exp Pharmacol. 2007, 177: 145-177.CrossRefPubMed
6.
Stefani A, Spadoni F, Bernardi G: Voltage-activated calcium channels: targets of antiepileptic drug therapy?. Epilepsia. 1997, 38 (9): 959-965.CrossRefPubMed
7.
Snutch TP, Reiner PB: Ca2+ channels: diversity of form and function. Curr Opin Neurobiol. 1992, 2 (3): 247-253.CrossRefPubMed
8.
Spina E, Perugi G: Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004, 6 (2): 57-75.PubMed
9.
Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen CL, American Academy of Neurology; American Epilepsy Society: Management issues for women with epilepsy–focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009, 50 (5): 1247-1255.CrossRefPubMed
10.
Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C, American Academy of Neurology; American Epilepsy Society: Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009, 50 (5): 1237-1246.CrossRefPubMed
11.
Samren EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granstrom ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D: Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia. 1997, 38 (9): 981-990.CrossRefPubMed
12.
Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C: Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008, 81 (1): 1-13.CrossRefPubMedPubMedCentral
13.
Adab N, Jacoby A, Smith D, Chadwick D: Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001, 70 (1): 15-21.CrossRefPubMedPubMedCentral
14.
Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW: The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004, 75 (11): 1575-1583.CrossRefPubMedPubMedCentral
15.
Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M, Nylund T, Bardy A, Kaaja E, Granstrom ML: Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004, 62 (1): 28-32.CrossRefPubMed
16.
Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, for the NEAD Study Group: Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009, 360 (16): 1597-1605.CrossRefPubMedPubMedCentral
17.
Holmes LB, Wyszynski DF, Lieberman E: The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol. 2004, 61 (5): 673-678.CrossRefPubMed
18.
Reinisch JM, Sanders SA, Mortensen EL, Rubin DB: In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA. 1995, 274 (19): 1518-1525.CrossRefPubMed
19.
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006, 77 (2): 193-198.CrossRefPubMed
20.
Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC, NEAD Study Group: In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006, 67 (3): 407-412.CrossRefPubMedPubMedCentral
21.
Vajda FJ, Hitchcock A, Graham J, Solinas C, O’Brien TJ, Lander CM, Eadie MJ: Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol. 2006, 13 (6): 645-654.CrossRefPubMed
22.
Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyszynski DF: Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008, 70 (22 Pt 2): 2152-2158.CrossRefPubMed
23.
Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A, Liporace JD, Sam M, Kalayjian LA, Thurman DJ, Moore E, Loring DW, NEAD Study Group: Antiepileptic drug use in women of childbearing age. Epilepsy Behav. 2009, 15 (3): 339-343.CrossRefPubMedPubMedCentral
24.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L: Reporting Guidelines for Systematic Review Protocols. 19th Cochrane Colloquium: 19–22. 2011, October ; Madrid, Spain
25.
Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR, CPNDS Consortium: The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid. 2010, 20 (7): 681-687.CrossRefPubMed
26.
Eypasch E, Lefering R, Kum CK, Troidl H: Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995, 311 (7005): 619-620.CrossRefPubMedPubMedCentral
27.
Atkins D: Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs. Med Care. 2007, 45 (10 Supl 2): S16-S22.CrossRefPubMed
28.
29.
30.
31.
32.
33.
Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C: An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009, 62 (9): 944-952.CrossRefPubMed
34.
35.
Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J: Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev. 2004, 3: CD004848-PubMed
36.
Banach R, Boskovic R, Einarson T, Koren G: Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf. 2010, 33 (1): 73-79.CrossRefPubMed
37.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33 (1): 159-174.CrossRefPubMed
38.
39.
Stone PW: Popping the (PICO) question in research and evidence-based practice. Appl Nurs Res. 2002, 15 (3): 197-198.CrossRefPubMed
40.
41.
42.
Santaguida PL, Raina P, Ismaila A: The Development of the McHarm Quality Assessment Scale for Adverse Events. 2008, Hamilton, Ontario: McMaster University
43.
Raudenbush SW: Analyzing Effect Sizes: Random Effects Models. The Handbook of Research Synthesis and Meta-analysis. Edited by: Cooper H, Hedges LV, Valentine JC. 2009, New York: Russell Sage Foundation, 295-315. 2
44.
Viechtbauer W: Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005, 30 (3): 261-293.CrossRef
45.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558.CrossRefPubMed
46.
Viechtbauer W: Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007, 26 (1): 37-52.CrossRefPubMed
47.
48.
Sweeting MJ, Sutton AJ, Lambert PC: What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004, 23 (9): 1351-1375.CrossRefPubMed
49.
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007, 26 (1): 53-77.CrossRefPubMed
50.
Littell JH, Corcoran J, Pillai V: Systematic Reviews and Meta-Analysis. 2008, New York: Oxford University PressCrossRef
51.
Carpenter J, Rucker G, Schwarzer G: Assessing the sensitivity of meta-analysis to selection bias: a multiple imputation approach. Biometrics. 2011, 67 (3): 1066-1072.CrossRefPubMed
52.
53.
Salanti G, Ades AE, Ioannidis JP: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64 (2): 163-171.CrossRefPubMed
54.
Salanti G: Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012, 3 (2): 80-97.CrossRefPubMed
55.
Song F, Altman DG, Glenny AM, Deeks JJ: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003, 326 (7387): 472-CrossRefPubMedPubMedCentral
56.
Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G: Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013, 42 (1): 332-345.CrossRefPubMed
57.
Dias S, Welton NJ, Caldwell DM, Ades AE: Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010, 29 (7–8): 932-944.CrossRefPubMed
58.
White IR, Barrett JK, Jackson D, Higgins JPT: Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012, 3 (2): 111-125.CrossRefPubMedPubMedCentral
59.
Jackson D, Barrett JK, Stephen R, White IR, Higgins JPT: A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med. 2014, In press
60.
White IR: Multivariate random-effects meta-regression: updates to mvmeta. Stata J. 2011, 11 (2): 255-270.
61.
62.
Yerby MS: Pregnancy, teratogenesis, and epilepsy. Neurol Clin. 1994, 12 (4): 749-771.PubMed
Metadata
Title
Comparative safety of anti-epileptic drugs among infants and children exposed in utero or during breastfeeding: protocol for a systematic review and network meta-analysis
Authors
Andrea C Tricco
Elise Cogo
Veroniki A Angeliki
Charlene Soobiah
Brian Hutton
Brenda R Hemmelgarn
David Moher
Yaron Finkelstein
Sharon E Straus
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2014
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/2046-4053-3-68

Other articles of this Issue 1/2014

Systematic Reviews 1/2014 Go to the issue

Methodology

A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL

Research

Assessment of a method to detect signals for updating systematic reviews

Research

Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis

Research

The challenges of including sex/gender analysis in systematic reviews: a qualitative survey

Protocol

The cost of data collection for performance monitoring in hospitals: protocol for a systematic review

Protocol

Instruments to measure patient experience of health care quality in hospitals: a systematic review protocol